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Abstract
Background: BRCA1 and BRCA2 are the two most important genes associated with familial breast
and ovarian cancer susceptibility. In addition, PALB2 has recently been identified as a breast cancer
susceptibility gene in several populations. Here we have evaluated whether large genomic
rearrangement in these genes could explain some of Finnish breast and/or ovarian cancer families.
Methods: Altogether 61 index patients of Northern Finnish breast and/or ovarian cancer families
were analyzed by Multiplex ligation-dependent probe amplification (MLPA) method in order to
identify exon deletions and duplications in BRCA1,  BRCA2 and PALB2. The families have been
comprehensively screened for germline mutation in these genes by conventional methods of
mutation analysis and were found negative.
Results: We identified one large deletion in BRCA1, deleting the most part of the gene (exon 1A-
13) in one family with family history of ovarian cancer. No large genomic rearrangements were
identified in either BRCA2 or PALB2.
Conclusion: In Finland, women eligible for BRCA1 or BRCA2 mutation screening, when found
negative, could benefit from screening for large genomic rearrangements at least in BRCA1. On the
contrary, the genomic rearrangements in PALB2 seem not to contribute to the hereditary breast
cancer susceptibility.
Background
Breast cancer is the most frequently occurring malignancy
in women. BRCA1 and BRCA2 are the two major suscep-
tibility genes, accounting for varying fraction of familial
breast and ovarian cancer cases in different populations.
In Finland, mutations in these genes explain approxi-
mately 20% of breast and ovarian cancer families [1,2].
Most of the alterations identified in BRCA1 and BRCA2
are point mutations and small insertions/deletions, but
increasing number of large genomic rearrangements in
both genes have been identified in different populations
[3-6]. Rearrangements have been described throughout
the genes, and majority of them are unique and introduce
a premature termination codon in the reading frame [3,6].
The proportion of BRCA1 and BRCA2 mutations due to
genomic rearrangements is not expected to vary markedly
in different populations, although there might be accu-
mulation of certain mutations due to a founder effect.
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Previous studies performed in the Finnish population
have not observed large genomic rearrangements in
BRCA1 or BRCA2 [7-9]. However, in the previous studies
either the method used (Southern blotting analysis on
part of these genes) has not allowed sensitive testing [7],
the study has concentrated only on male breast cancer
cases [9] or the analyzed samples were derived from a geo-
graphically restricted area [8]. In Finland, the difference in
geographical distribution has been reported for several
cancer susceptibility alleles, including BRCA1,  BRCA2,
ATM and RAD50 mutations [2,10-12], which is the result
of strong founder effect and population history. The set-
tlement was restricted to the coastal areas during the 15th
century, and it was not until the 17th century that the vast
inland regions were gradually inhabited by a relatively
small number of individuals, resulting in several region-
ally occurring founder mutations [2]. Consequently, large
genomic rearrangements in BRCA1 and BRCA2 might still
be at least partly responsible for the hereditary predisposi-
tion to breast and ovarian cancer in Finland.
PALB2 was recently identified as a breast cancer suscepti-
bility gene [13,14] and mutations in it have since been
reported in other populations [15-17]. PALB2 encodes a
protein that binds to BRCA2 and this interaction is crucial
for certain BRCA2 DNA damage response and tumor sup-
pression functions [18]. The breast cancer associated
mutations identified in PALB2 are expected to be deleteri-
ous, and all result in protein truncations. The risk esti-
mates for PALB2  mutations have ranged from two- to
fourfold, although some PALB2 mutations have been sug-
gested to have higher penetrance [13-15]. Here, we
wanted to investigate whether large genomic rearrange-
ments in PALB2 could also explain some of the Finnish
breast and/or ovarian cancer families.
In the current study we have used Multiplex ligation-
dependent probe amplification (MLPA) in order to iden-
tify exon deletions and duplications in the BRCA1, BRCA2
and PALB2 genes. MLPA has been proven to be very useful
in detecting copy number changes in genomic sequences
[19]. The families selected to this study have been compre-
hensively screened for germline mutation in these genes
by conventional methods of mutation analysis [2,13] and
were found negative.
Methods
Breast and/or ovarian cancer families
Altogether 61 index patients of Northern Finnish breast
and/or ovarian cancer families were selected for the study.
These families have been screened for germline mutations
in BRCA1, BRCA2 and PALB2 and were found negative
[2,13]. 41 of the families had three or more cases of breast
and/or ovarian cancer in first- or second-degree relatives,
and 11 families had two cases of breast and/or ovarian
cancer in first- or second-degree relatives, of which at least
one with early disease onset (≤ 35 years), bilateral disease
or multiple primary tumors. Four families had one case of
breast and ovarian cancer each, three families had two
breast cancer cases, of which one diagnosed at young age
≤ 43 years, and two families showed one breast cancer
case (≤ 40 years) with multiple primary tumors. The
affected index cases of these families were analyzed, and
the patient with youngest age at diagnosis or the one with
multiple tumors was selected as an index. The study has
been approved by the Ethical Board of the Northern
Ostrobothnia Health Care District and the Finnish Minis-
try of Social Affairs and Health. All patients provided
informed consent to participate in this study.
MLPA and data analysis
The SALSA MLPA kits for BRCA1 (primary screening kit
P002B and confirmation kit P087), BRCA2 (P045B) and
PALB2  (P057) kits (MRC-Holland, Netherlands) were
used according to the manufacturer's instructions. After
PCR amplification with IRD800 labeled primers the sam-
ples were analyzed with Li-Cor IR2 4200-S DNA Analysis
system (Li-Cor Inc., Lincoln, NE) and Gene Profiler 4.05
analysis program (Scanalytics, Inc., Fairfax, VA). For
BRCA1 analysis the used deletion control had deletions in
exons 1A-2, for BRCA2  analysis the control sample
showed constant 50% reduction in band intensity result-
ing from a SNP locating three base pairs from the ligation
site, and for PALB2 analysis the used control had hetero-
zygous deletions in exons 1–3 and 5–10 in addition to
homozygous deletion of exon 4.
The information regarding the integrated density of each
band received from GeneProfiler was analyzed by MLPA
spreadsheets (National Genetics Reference Laboratory) in
Excel Software according to the instructions. Dosage quo-
tients 0.35–0.65 were considered deleted and dosage quo-
tients 1.35–1.65 duplicated, and samples with quality
value (standard deviation of the control ligation prod-
ucts) exceeding 0.1 were rejected. For the DNA sample
positive for a genomic rearrangement, analysis was
repeated using an independent sample in an independent
assay.
Results
We have analyzed a total of 61 index patients for large
genomic rearrangements in BRCA1, BRCA2 and PALB2
genes by MLPA. In BRCA2 and PALB2 no deletions or
duplications were observed. We did, however, observe
one large deletion in BRCA1  (exon 1A-13) (Figure 1),
deleting the most part of the gene, including the promoter
region. This deletion spans over 43 kb. The initial obser-
vation with P002B kit was subsequently confirmed by the
BRCA1 confirmation kit P087. The patient carrying the
deletion allele was diagnosed with ovarian cancer at theBMC Cancer 2008, 8:146 http://www.biomedcentral.com/1471-2407/8/146
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age of 49 years. The family had strong history of cancer,
and there were altogether three cases of ovarian cancer
(Figure 2). DNA was not available for testing from any
other family members.
Discussion
Germline mutations in BRCA1  and  BRCA2  cause an
increased lifetime risk for breast and ovarian cancer [20].
In addition, PALB2 has recently been identified as a breast
cancer susceptibility gene in several populations, but its
association with increased risk for ovarian cancer has not
been established [13-17]. Although BRCA1 and BRCA2
rearrangements have previously been studied in the Finn-
ish population, none have so far been reported [7-9]. The
earlier studies have, however, been concentrating on fam-
ilies deriving from geographically restricted area or only
on male breast cancer patients, or have used the less sen-
sitive Southern blotting method. Therefore, a comprehen-
sive analysis of genomic rearrangements in the BRCA1
and BRCA2 genes in the Northern Finnish patient cohort
was needed. For PALB2 this is the first study designed to
detect large genomic rearrangements in the Finnish popu-
lation.
The index cases of 61 families included in this study were
analyzed for rearrangements in the three genes by MLPA,
and in one family we identified a large deletion in BRCA1.
The observed deletion removes most of the gene includ-
ing the promoter [21], thereby preventing the transcrip-
tion of BRCA1. The mutation positive patient displayed a
family history of ovarian cancer, which has been shown to
increase the likelihood of finding a BRCA1 mutation in a
family [22]. Deletions that remove the BRCA1 promoter
have previously been described, but the earlier studies
have not associated these changes with any particular phe-
notype [23-26]. Our result provide the first evidence that,
like in many other studied populations, large genomic
changes in BRCA1  do also exist in Finland. However,
these mutations seem to be rare, if not unique, as this
deletion was seen in only one out of 61 families.
To date, only three different BRCA1 mutations have been
identified in Northern Finnish breast and/or ovarian can-
cer families. Two of these mutations, 3745delT and 4216-
2ntA>G, represent recurrent Finnish founder mutations
[1,2,27], accounting for three mutation positive families
each [2]. The third BRCA1 mutation is the currently iden-
tified large deletion of exons 1A-13, which represents
14.3% (1/7) of the identified Northern Finnish BRCA1
positive families. Even though the deletion allele was
observed only in one out 61 currently analyzed families,
our results suggests that women eligible for BRCA1  or
BRCA2 mutation screening, when found negative, could
Family exhibiting exon 1A-13 deletion in BRCA1 Figure 2
Family exhibiting exon 1A-13 deletion in BRCA1. 
Index case is shown with an arrow.
Ovca 49 y
Ovca 55 y Lung Leukemia
Ovca 56 y
Bladder 40 y
MLPA analysis of a patient with family history of ovarian cancer Figure 1
MLPA analysis of a patient with family history of ovarian cancer. A large genomic deletion of exons 1A to 13 in 
BRCA1 was found. Y-axis dosage quotients, X-axis used control probes (blue) and individual BRCA1 exons (green).BMC Cancer 2008, 8:146 http://www.biomedcentral.com/1471-2407/8/146
Page 4 of 5
(page number not for citation purposes)
benefit from screening for large genomic rearrangements,
at least in BRCA1. Additional work is still needed in order
to determine the prevalence of BRCA2 rearrangements in
Finland, as the current study was based only on relatively
small number of families.
Despite the identification of one large genomic deletion
in BRCA1, our results support the previous conclusions
that the genomic rearrangements in BRCA1 and BRCA2
are not a major cause for increased breast cancer suscepti-
bility in Finland, and that the previously reported Finnish
founder mutations represent the majority of BRCA1 and
BRCA2 positive families [1,2,7-9,27]. No exon deletions
or duplications of the PALB2 gene were identified in the
studied index cases of 61 families. This suggests that
genomic rearrangements in PALB2 are very rare, which
has also been indicated by a previous study [16]. At least
in the Finnish population the major breast cancer associ-
ated aberration in PALB2 appears to be the previously
reported founder truncation mutation [13].
Conclusion
In Finland, women eligible for BRCA1 or BRCA2 muta-
tion screening, when found negative, could benefit from
screening for large genomic rearrangements at least in
BRCA1. In contrast, the genomic rearrangements in
PALB2 seem not to contribute to the hereditary breast can-
cer susceptibility in Finland.
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